Research and Markets (http://www.researchandmarkets.com/research/87ea7e/epilepsy_drug_pi)
has announced the addition of GlobalData 's new report "Epilepsy
- Drug Pipeline Analysis and Market Forecasts to 2015" to their
offering.
“Epilepsy
- Drug Pipeline Analysis and Market Forecasts to 2015”
"Epilepsy
- Drug Pipeline Analysis and Market Forecasts to 2015" is an
essential source of information and analysis on the global epilepsy
market. The report identifies the key trends shaping and driving the
global epilepsy market. The report also provides insight on the
prevalent competitive landscape and the emerging players expected to
bring a significant shift in the market positioning of the existing
market leaders. Most importantly, the report provides valuable insight
on the pipeline products within the global epilepsy sector.
This report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by a
team of industry experts.
Epilepsy Therapeutics Market holds Significant Low Market Potential
Epilepsy or seizure disorder is a common Central Nervous System (CNS)
disorder and is usually diagnosed after a person has had at least two
seizures not caused by known conditions. The seizure in epilepsy may be
related to a brain injury or a familial history but generally its cause
is completely unknown. There are two types of epilepsy: generalized
(comprising grand mal and petit mal; approximately 65% of patients) and
partial (comprising simple and complex; approximately 35% of patients).
In the current market, generalized epilepsy is fairly well controlled,
though sometimes at the expense of unpleasant side effects. The same is
not true for partial epilepsy. The epilepsy market has relatively medium
unmet need. Many new antiepileptic drugs (AEDs) have become available
over the past 15 years, and the pipeline for new AEDs continues to be
growing at a steady rate. The antiepileptic drug market is currently
under pressure from generic competition, which typically has 40-50%
cheaper drugs then the branded products. This can drive down prices and
decrease sales of branded drugs.
However, currently available medication is not only indended for
epilepsy but also for other conditions such as pain and bipolar
disorder. The approval of antiepileptic drugs for new indications, for
use as monotherapy, refractory epilepsy, and in children (LGS), will
potentially provide growth for the epilepsy market. Currently available
marketed AEDs result in seizure-free status in no more than 15 to 20% of
patients with partial complex seizures. Overall, across all types of
epilepsy, approximately 30% of epileptic patients are still not seizure
free, despite a large range of old and new drugs.
Scope
The scope of the report includes: